| EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen |
| AKTIEN IM FOKUS: Zinsanstieg birgt Gefahren für sichere Aktienhäfen | FRANKFURT (dpa-AFX) - Steigende Zinsen an den Kapitalmärkten haben zum Wochenbeginn die Aktienkurse von als sichere Anlagen geltenden Unternehmen belastet. Dazu zählen unter anderen die Immobilienwerte... ► Artikel lesen |
| EQS-PVR: Fresenius Medical Care AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Fresenius Medical Care AG
Fresenius Medical Care AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act]... ► Artikel lesen |
| PROCEPT BioRobotics Reports First Quarter 2026 Financial Results | SAN JOSE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen |
| PROCEPT BioRobotics: EAU Guidelines Upgrade Aquablation Therapy to Strong Surgical Recommendation for BPH | Updated European Association of Urology guidelines reflect growing clinical evidence supporting Aquablation therapy in the surgical treatment of benign prostatic hyperplasiaSAN JOSE, Calif., March 23... ► Artikel lesen |
| PROCEPT BioRobotics Announces International Launch of the HYDROS Robotic System, Expanding Global Access to AI-Enabled Aquablation Therapy | UK marks first international launch of the HYDROS Robotic System, with additional international expansion planned in 2026SAN JOSE, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq:... ► Artikel lesen |
| Heartflow, Inc.: Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half | FUSION trial presented at ESC and published in Journal of the American College of Cardiology demonstrates adding non-invasive lesion-specific physiology resolves critical diagnostic uncertainty, supporting... ► Artikel lesen |
| Biotech Stocks At 52-Week Highs - Vogenx, Pharvaris, Solventum, Inhibikase Therapeutics, HeartFlow | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 24, 2026, driven by positive results from clinical trials or an upcoming conference participation. Vogenx... ► Artikel lesen |
| Heartflow, Inc.: Heartflow Reports Second Quarter 2026 Financial Results and Raises Full Year 2026 Guidance | SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing coronary artery disease (CAD), today reported financial results... ► Artikel lesen |